Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Proposed acquisition of Apogee highlighted as the core disclosure.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Proposed acquisition of Apogee highlighted as the core disclosure
- AbbVie expects adjusted diluted EPS accretion beginning in 2032
- Zumilokibart (APG777) and APG273 represent key pipeline assets under acquisition
- Closing depends on regulatory and Apogee stockholder approvals
- Material risks include clinical-trial failure, integration costs, litigation, competing bids, and termination rights
Item EX-99.1 · Exhibit EX-99.2
- AbbVie to acquire Apogee for $135.11 per share in cash, valuing equity at approximately $10.9 billion
- Strategic expansion into atopic dermatitis and asthma, diversifying AbbVie’s immunology portfolio and accelerating respiratory exposure
- Key assets include late-stage IL-13 antibody zumilokibart and APG273, an IL-13/TSLP combination with quarterly or twice-yearly dosing potential
- Transaction expected to close in third quarter 2026, subject to Apogee shareholder and regulatory approvals
- Adjusted diluted EPS accretion projected beginning in 2032, making long-term clinical and commercial execution critical
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.